Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
I'm PortAI, I can summarize articles.
Eli Lilly has signed a deal worth up to $1.12 billion with Seamless Therapeutics to develop treatments for hearing loss using gene-editing technology. The agreement includes an upfront payment and funding for research and development, with additional payments tied to development milestones. This partnership allows Lilly to enhance its pipeline of genetic medicines while Seamless aims to advance its first experimental drug. Lilly has previously invested in gene-editing therapies, including acquisitions of Verve Therapeutics and Akouos.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments